Edition:
United Kingdom

AMAG Pharmaceuticals Inc (AMAG.OQ)

AMAG.OQ on NASDAQ Stock Exchange Global Select Market

20.15USD
8:25pm BST
Change (% chg)

$0.15 (+0.75%)
Prev Close
$20.00
Open
$20.00
Day's High
$20.40
Day's Low
$19.55
Volume
57,547
Avg. Vol
256,856
52-wk High
$24.83
52-wk Low
$11.93

Chart for

About

AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company's segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia... (more)

Overall

Beta: 0.11
Market Cap(Mil.): $659.62
Shares Outstanding(Mil.): 34.09
Dividend: --
Yield (%): --

Financials

  AMAG.OQ Industry Sector
P/E (TTM): -- 29.67 32.21
EPS (TTM): -6.18 -- --
ROI: -11.59 13.44 13.05
ROE: -25.14 15.16 14.90

BRIEF-AMAG Pharmaceuticals Submits NDA To FDA For Bremelanotide

* AMAG PHARMACEUTICALS SUBMITS A NEW DRUG APPLICATION TO THE U.S. FOOD AND DRUG ADMINISTRATION FOR BREMELANOTIDE FOR THE TREATMENT OF HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) IN PREMENOPAUSAL WOMEN Source text for Eikon: Further company coverage:

26 Mar 2018

BRIEF-AMAG Pharmaceuticals and Sandoz Enters Stipulation Of Dismissal

* AMAG PHARMACEUTICALS - ‍CO, SANDOZ ENTERED STIPULATION OF DISMISSAL, PURSUANT TO SETTLEMENT AGREEMENT, THAT DISMISSES, RESOLVES PATENT LITIGATION​

23 Mar 2018

BRIEF-AMAG Reports Q4 Earnings Of $0.10 Per Share

* TOTAL GAAP REVENUES FOR Q4 OF 2017 WERE $158.3 MILLION, COMPARED WITH $151.6 MILLION

27 Feb 2018

BRIEF-AMAG Gets FDA Approval Of Makena Subcutaneous Auto-Injector

* AMAG PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF MAKENA® (HYDROXYPROGESTERONE CAPROATE INJECTION) SUBCUTANEOUS AUTO-INJECTOR TO REDUCE THE RISK OF PRETERM BIRTH IN CERTAIN AT-RISK WOMEN

14 Feb 2018

BRIEF-AMAG Pharmaceuticals Announces FDA Approval Of Supplemental New Drug Application (SNDA) For Feraheme

* AMAG PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) FOR FERAHEME® (FERUMOXYTOL INJECTION) Source text for Eikon: Further company coverage:

05 Feb 2018

BRIEF-AMAG Pharmaceuticals Sees Q4 2017 Revenue $156 Mln to $163 Mln

* AMAG PHARMACEUTICALS ANNOUNCES PRELIMINARY 2017 FINANCIAL RESULTS AND PROVIDES 2018 GUIDANCE

08 Jan 2018

UPDATE 1-Around 6,000 Swiss VW owners seek damages in emissions scandal

* VW says 98 percent of affected vehicles already fixed (Adds VW reaction)

30 Dec 2017

BRIEF-New Patent Issued To Amag Pharmaceuticals Entitled "Methods Of Reducing Risk Of Preterm Birth"

* NEW PATENT ISSUED TO AMAG PHARMACEUTICALS ENTITLED "METHODS OF REDUCING RISK OF PRETERM BIRTH" Source text for Eikon: Further company coverage:

20 Dec 2017

BRIEF-Amag Pharmaceuticals Q3 loss per share $4.31

* Amag Pharmaceuticals announces third quarter 2017 financial results and business highlights

02 Nov 2017

Earnings vs. Estimates